-
Related books
Staphylococci in Human Disease
by Kent B. Crossley, Kimberly K. Jefferson, Gordon L. Archer, and Vance G. Fowler (Hardcover - Oct 26, 2009)
Excerpt:
... "agents to reduce the likelihood of selection for rifampin resistance. Mupirocin Mupirocin (pseudomonic acid) is an antibiotic derived from cultures of" ...
More about this bookMethicillin-resistant Staphylococcus Aureus (Infectious Disease and Therapy)
by M. Cafferkey (Hardcover - Jan 31, 1992)
Excerpt:
... "chemical agents. An undoubted advance in this field has been mupirocin, which was first licenced in the United Kingdom in 1985" ...
More about this bookClinical Management of Uncomplicated Skin And Skin Structure Infections
by Dirk Elston, Stephen K. Tyring, Whitney A. High, and Tammie Ferringer (Paperback - Mar 20, 2007)
Excerpt:
... "Topical Agents Used to Treat Uncomplicated Skin and Skin-Structure Infections Mupirocin" ...
More about this bookEvidence-Based Infectious Diseases (Evidence-Based Medicine)
by Mark Loeb, Fiona Smaill, and Marek Smieja (Paperback - Sep 28, 2009)
Excerpt:
... "CI 0.774.03) [4]; however, strains of S. aureus resistant to mupirocin are Evidence-Based Infectious Diseases, 2nd edition. Edited by Mark Loeb," ...
More about this bookReemergence of Established Pathogens in the 21st Century (Emerging Infectious Diseases of the 21st Century)
by I.W. Fong and Karl Drlica (Hardcover - Jun 2003)
Excerpt:
... "(Ciprolloxacin, Ofloxacin, NortIoxacin, etc.) 109 2.6.8. Fusidic acid 110 2.6.9. Mupirocin 110 2.6.10. Glycopeptides (Vancomycin, Teicoplanin) 110 2." ...
More about this bookThe Year in Infection 2003
by C.P. Conlon (Hardcover - Sep 25, 2003)
Excerpt:
... "(Table 10.2). A randomized controlled trial of topical exit site mupirocin application in patients with tunnelled," ...
More about this bookBacterial Resistance to Antimicrobials, Second Edition
by Kim Lewis, Abigail A. Salyers, Harry Taber, and Richard G. Wax (Hardcover - Dec 5, 2007)
Excerpt:
... "151 Methicillin Resistance in Staphylococci ................................................ 151 Mupirocin Resistance in Staphylococci ................................................. 153 trimethoprim Resistance ......................................................." ...
More about this bookPreop application of mupirocin cuts infections.(Clinical Rounds): An article from: OB GYN News
by Heidi Splete (Digital - April 4, 2006) - HTML
More about this bookMupirocin: Webster's Timeline History, 1985 - 2007
by Icon Group International (Digital - Jul 11, 2009) - Download: PDF
More about this bookbactroban (Mupirocin): International Symposium Proceedings (Current clinical practice series)
by Richard L. Dobson and etc. (Hardcover - April 1985)
More about this bookMupirocin
by Wilkinson (Paperback - Jan 1, 1996)
More about this bookThe clinical efficacy of mupirocin in the treatment of primary and secondary skin infections (International clinical practice series)
(Paperback - 1996) - Import
More about this book
medicine: mupirocin
mupirocin description
Go to trade names and prices
Mupirocin (Bactroban or Centany) is an antibiotic originally isolated from Pseudomonas fluorescens NCIMB 10586, developed by Beecham.
Mupirocin is bacteriostatic at low concentrations and bactericidal at high concentrations. It is used topically and is effective against Gram-positive bacteria, including MRSA. Mupirocin is a mixture of several pseudomonic acids, with pseudomonic acid A (PA-A) constituting greater than 90% of the mixture. Also present in mupirocin are pseudomonic acid B with an additional hydroxyl group at C8, pseudomonic acid C with a double bond between C10 and C11, instead of the epoxide of PA-A, and pseudomonic acid D with a double bond at C4` and C5` in the 9-hydroxy-nonanoic acid portion of mupirocin.
Figure 1. The structure of pseudomonic acid A-D, labeled A-D, respectively.
Mechanism
Mupirocin has been shown to strongly inhibit protein and RNA synthesis in Staphylococcus aureus while DNA and cell wall formation were also negatively impacted to a lesser degree. The inhibition of RNA synthesis was shown to be a protective mechanism in response to a lack of one amino acid, isoleucine. In vivo studies in Escherichia coli demonstrated that pseudomonic acid inhibits isoleucine t-RNA synthetase (IleRS). This mechanism of action is shared with furanomycin, an analog of isoleucine
Uses
Mupirocin is used as a topical treatment for bacterial skin infections, for example, furuncle, impetigo, open wounds etc. It is also useful in the treatment of methicillin-resistant Staphylococcus aureus (MRSA), which is a significant cause of death in hospitalized patients who have received systemic antibiotic therapy. It is suggested, however, that mupirocin cannot be used for extended periods of time, or indiscriminately, as resistance does develop, and could, if it becomes widespread, destroy mupirocin's value as a treatment for MRSA. It may also result in overgrowth of non-susceptible organisms.
Resistance
Shortly after the clinical use of Mupirocin began, strains of Staphylococcus aureus that were resistant to mupirocin emerged. Two distinct populations of mupirocin-resistant S. aureus were isolated. One strain possessed low-level resistance, MuL, (MIC = 8-256 mg/L) and another possessed high-level resistance, MuH, (MIC > 256 mg/L). Resistance in the MuL strains is probably due to mutations in the organism’s wild-type isoleucinyl-tRNA synthetase. In E. coli IleRS, a single amino acid mutation was shown to alter mupirocin resistance. MuH is linked to the acquisition of a separate Ile synthetase gene, mupA. Mupirocin is not a viable antibiotic against MuH strains. Other antibiotic agents such as azelaic acid, nitrofurazone, silver sulfadiazine, and ramoplanin have been shown to be effective against MuH strains.
The mechanism of mupirocin differs from other clinical antibiotics rendering cross-resistance to other antibiotics unlikely. However, the MupA gene may co-transfer with other antibacterial resistance genes. This has been observed already with resistance genes for triclosan, tetracycline, and trimethoprim.
Biosynthesis
Biosynthesis of Pseudomonic acid A
The 74 kb mupirocin gene cluster contains six multi-domain enzymes and twenty six other peptides (Table 1). Four large multi-domain type I polyketide synthase (PKS) proteins are encoded, as well as several single function enzymes with sequence similarity to type II PKSs. It is therefore believed that mupirocin is constructed by a mixed type I and type II PKS system. The mupirocin cluster exhibits an atypical acyltransferase (AT) organization, in that there are only two AT domains and both are found on the same protein, MmpC. These AT domains are the only domains present on MmpC, while the other three type I PKS proteins contain no AT domains. The mupirocin pathway also contains several tandem acyl carrier protein doublets or triplets. This may be an adaptation to increase the throughput rate or to bind multiple substrates simultaneously.
Table 1. The biosynthetic gene cluster of mupirocinPseudomonic acid A is the product of an esterification between the 17C polyketide monic acid and the 9C fatty acid 9-hydroxy-nonanoic acid. The possibility that the entire molecule is assembled as a single polyketide with a Baeyer-Villiger oxidation inserting an oxygen into the carbon backbone has been ruled out because C1 of monic acid and C9’ of 9-hydroxy-nonanoic acid are both derived from C1 of acetate.
Monic acid biosynthesis
Biosynthesis of the 17C monic acid unit begins on MmpD (Figure 2). One of the AT domains from MmpC may transfer an activated acetyl group from acetyl-Coenzyme A (CoA) to the first ACP domain. The chain is extended by malonyl-CoA, followed by a SAM-dependent methylation at C12 (see Figure 1 for PA-A numbering) and reduction of the B-keto group to an alcohol. The dehydration (DH) domain in module 1 is predicted to be non-functional due to a mutation in the conserved active site region. Module 2 adds another two carbons by malonyl-CoA extender unit, followed by ketoreduction (KR) and dehydration. Module three adds a malonyl-CoA extender unit, followed by SAM-dependent methylation at C8, ketoreduction, and dehydration. Module 4 extends the molecule with a malonyl-CoA unit followed by ketoreduction.
Assembly of monic acid is continued by the transfer of the 12C product of MmpD to MmpA. Two more rounds of extension with malonyl-CoA units are achieved by module 5 and 6. Module 5 also contains a KR domain.
Figure 2. The domain structure of MmpA, MmpC, and MmpD for the synthesis of monic acid. The biosynthesis of monic acid is not colinear but has been rearranged in this diagram. The protein name is displayed inside of the arrow with module and domain structure listed below. ACP=acyl carrier protein, AT=acyl transferase, DH=dehydratase, ER=enoyl reductase, HMG=3-hydroxy-3-methylglutaric acid, MeT=methyl transferase, KR=ketoreductase, KS=ketosynthase, TE=thioesterase.
Post-PKS tailoring
The keto group at C3 is replaced with a methyl group in a multi-step reaction (Figure 3). MupG begins by decarboxylating a malonyl-ACP. The alpha carbon of the resulting acetyl-ACP is linked to C3 of the polyketide chain by MupH. This intermediate is dehydrated and decarboxylated by MupJ and MupK, respectively.
Figure 3. The C15 methyl group of monic acid is attached to C3 by the following reaction scheme. MupH is an 3-hydroxy-3-methylglutarate-Coenzyme A synthase, MupJ and MupK are Enoyl-CoA hydratases.
The formation of the pyran ring requires many enzyme mediated steps (Figure 4). The double bond between C8 and C9 is proposed to migrate to between C8 and C16. Gene knockout experiments of mupO, mupU, mupV, and macpE have eliminated PA-A production. PA-B production is not removed by these knockouts, demonstrating that PA-B is not created by hydroxylating PA-A. A knockout of mupW eliminated the pyran ring, identifying MupW as being involved in ring formation. It is not known if this occurs before or after the esterification of monic acid to 9-hydroxy-nonanoic acid.
Figure 4. The pyran ring of mupirocin is generated in this proposed multistep reaction [15]. Gene knockouts of mupO, mupU, mupV and macpE abolish PA-A production but not PA-B production, demonstrating that PA-B is a precursor to PA-A.
The epoxide of PA-A at C10-11 is believed to be inserted after pyran formation by a cytochrome P450 such as MupO. A gene knockout of mupO abolished PA-A production but PA-B, which also conatins the C10-C11 epoxide, remained. This indicates that MupO is either not involved or is not essential for this epoxidation step.
9-Hydroxy-nonanoic acid biosynthesis
The nine carbon fatty acid 9-hydroxy-nonanoic acid (9-HN) is derived as a separate compound and later esterified to monic acid to form pseudomonic acid. C labeled acetate feeding has shown that C1-C6 are constructed with acetate in the canonical fashion of fatty acid synthesis. C7’ shows only C1 labeling of acetate while C8’ and C9’ show a reversed pattern of 13C labeled acetate. It is speculated that C7-C9 arises from a 3-hydroxypropionate starter unit, which is extended three times with malonyl-CoA and fully reduced to yield 9-HN. It has also been suggested that 9-HN is initiated by 3-hydroxy-3-methylglutaric acid (HMG). This latter theory was not supported by feeding of [3-C] or [3,6-C2]-HMG.
MmpB is proposed to catalyze the synthesis of 9-HN (Figure 5). MmpB contains a KS, KR, DH, 3 ACPs, and a thioesterase (TE) domain. It does not contain an enoyl reductase (ER) domain which would be required for the complete reduction to the nine carbon fatty acid. MupE is a single domain protein that shows sequence similarity to known ER domains and may complete the reaction. It also remains possible that 9-hydroxy-nonanoic acid is derived partially or entirely from outside of the mupirocin cluster.
Figure 5. MmpB is proposed to synthesize 9-HN with a 3-hydroxy-propionate starter unit and three malonyl-CoA extenter units. The domain structure of MmpB is shown below along side with MupE, the proposed enoyl reductase required for complete saturation of 9-HN. ACP=acyl carrier protein, DH=dehydratase, ER=enoyl reductase, KR=ketoreductase, KS=ketosynthase, TE=thioesterase.
Figure 5. MmpB is proposed to synthesize 9-HN with a 3-hydroxy-propionate starter unit and three malonyl-CoA extenter units. The domain structure of MmpB is shown below along side with MupE, the proposed enoyl reductase required for complete saturation of 9-HN. ACP=acyl carrier protein, DH=dehydratase, ER=enoyl reductase, KR=ketoreductase, KS=ketosynthase, TE=thioesterase.Sources
The original manufacturer's (GlaxoSmithKline) product is Bactroban. It is now available as a generic. One source is manufactured by Ortho-McNeil Pharmaceutical called Centany. Another is from Teva Pharmaceutical Industries which is simply called Mupirocin Ointment.
| Name | Information | Price* | Quantity |
| Bactroban cream 2% | 15 grams (mupirocin) | $16 | 15 grams |
| Bactroban Nasal Ointment 2% | 3 grams (Mupirocin) | $22 | 3 grams |
| Bactroban ointment 2% | 15 grams (mupirocin) | $17 | 15 grams |
| Generic Mupirocin Ointment 2% | 22 grams | $29 | 22 grams |
*) Prices related to some of online drugstores. There are only approximate prices. For some of drugs is needed a prescription.
Tags
Keywords related to mupirocin
tiratricol circanol calderol acarbose benzatropine pindac ascorbic acid nadroparin calcium pargyline combivir atorolimumab ansaid butalamine amiphenazole aldosterone afrinol tussionex mepyramine buclizine pefloxacin diclazuril placidyl videx trandate tylox cefdaloxime tolonidine ciramadol anatumomab mafenatox captopril dirithromycin condylox opium ibalizumab clotrimazole darvon trileptal technetium 99mtc exametazime aloxiprin polysorbate 20 arava mylotarg polygeline tybamate lovastatin camylofin gadoversetamide carbastat